Ex-EU drug watchdog head's consulting gig scrutinized

The European Medicines Agency has received some fresh requests to investigate former head Thomas Lonngren, who is now an industry consultant, for potential conflicts of interest committed before he left the agency late last year. Although the EMA has already consented to Lonngren's role as a consultant to drug companies, advocacy groups believe he bent some ethics rules when he arranged for the position while still working for the agency. They want the agency to take another look into the matter, Pharmalot reported. Article

Suggested Articles

Look out, diabetes market: Novo Nordisk won its FDA nod for highly anticipated Rybelsus to control blood sugar in patients with Type 2 diabetes.

Insys is in fire sale mode as part of its bankruptcy plan, and now it’s been given the go-ahead to sell the opioid that helped get it there.

GSK CEO Emma Walmsley could soon have a new title: Microsoft board member. The software giant has nominated her to its board of directors.